Remus wins 24-product Bolivia tender as revenue rises 53.45% in H1 FY27

Remus Pharmaceuticals Limited won a Bolivia tender for 24 products in H1 FY27, while consolidated revenue rose 53.45% year on year to Rs 614.12 crore for the half year ended September 30, 2026. The company also reported a Peru plant approval, a Venezuelan government tender and planned own-label launches in Guatemala.

What did Remus win in Bolivia during H1 FY27?

Remus won a tender covering 24 products in Bolivia during H1 FY27. The November 3, 2026 release did not disclose the tender value, product names, customer, supply schedule or expected revenue contribution, so the announcement confirms the award but not its financial scale.

Bolivia is among the markets where Remus has a consolidated subsidiary, Relius Pharma SRL, for the half year ended September 30, 2026. Remus operates in one pharmaceutical-product segment and does not report country-level revenue, profit or order-book figures, leaving the contribution from Bolivia unquantified.

Remus said initial setup and operating costs for its Bolivia and Guatemala subsidiaries affected consolidated earnings in H1 FY27. Consolidated revenue nevertheless increased by Rs 213.92 crore from Rs 400.20 crore in H1 FY26 to Rs 614.12 crore in H1 FY27, although the company did not separate revenue linked to the 24-product tender.

How is Remus expanding access in Peru and Venezuela?

Remus said Peru's Digemid approved its plant and that it was filling 60+ products in Peru during H1 FY27. The release does not identify the facility, name the products, confirm their launch status or provide a Peru revenue target, but it connects the approval with an existing product-filling activity.

Remus also in-licensed several molecules for Peru, Mexico, Chile and Vietnam, supported by bioequivalence, or BE, studies. Management said these additions strengthened the anti-infective and anti-allergy portfolio, but did not identify the molecules, licensors, registration timetable or country-level sales outlook.

In Venezuela, Remus secured a direct government tender, reported product registrations and approvals, and executed supply orders for Rotigotine Patches. It described Rotigotine as its second patch launch in Venezuela and said it had initiated further filings in Venezuela and other markets, without disclosing the tender value, order value or supply date.

Remus also reported approval for semaglutide tablets and injections in its biological-products update. Commercialisation is planned soon rather than confirmed as having started, and the company did not provide a launch date, sales projection or product-specific revenue estimate.

How did Remus's H1 FY27 financial performance compare?

Remus reported consolidated revenue of Rs 614.12 crore in H1 FY27, against Rs 400.20 crore in H1 FY26 and Rs 453.43 crore in H2 FY26. Revenue therefore increased 53.45% year on year and 35.44% from the preceding half year.

Consolidated earnings before interest, tax, depreciation and amortisation, or EBITDA, rose 11.22% year on year to Rs 29.93 crore and 0.50% from Rs 29.78 crore in H2 FY26. Profit after tax, or PAT, increased 14.22% year on year to Rs 24.66 crore and 0.32% from Rs 24.58 crore in H2 FY26.

Remus attributed the slower growth in consolidated EBITDA and PAT relative to revenue to initial setup and operating costs at Espee Global Clinical Trial Services Private Limited and the Bolivia and Guatemala subsidiaries. Standalone revenue was Rs 62.08 crore in H1 FY27, up 32.51% from Rs 46.85 crore in H1 FY26, while standalone PAT rose 56.37% to Rs 18.81 crore.

What launches and portfolio additions is Remus planning?

Remus plans to introduce 5+ new brands in Guatemala under its own label. Relius Pharmaceuticals Limitada in Guatemala was included in the H1 FY27 consolidated financial results, but the company did not disclose brand names, therapeutic categories, launch dates, marketing spending or sales targets.

In the Dominican Republic, Remus received trademarks and brand approvals and plans a business-to-consumer, or B2C, launch soon. The release does not confirm that sales have begun, and it gives no timetable or estimate of the potential contribution from the planned B2C activity.

Remus said it is discussing the in-licensing of additional biosimilar products that could add to its portfolio. The November 3, 2026 release does not state the number of products under discussion, the counterparties, the markets involved or whether any agreement has been signed.

Conclusion

The H1 FY27 announcement combines reported financial growth with a wider set of international commercial steps. Remus recorded a 24-product Bolivia tender, a Digemid plant approval and 60+ products being filled in Peru, a Venezuelan government tender and Rotigotine supply orders, while consolidated revenue reached Rs 614.12 crore.

The next items to watch are commercialisation planned soon for semaglutide tablets and injections, the planned Dominican Republic B2C launch and the introduction of 5+ own-label brands in Guatemala. Management said subsidiaries funded over the previous six months and one year would begin contributing substantially to revenue and PAT, but did not provide a timetable or quantified target.